CIZ.LSE Cizzle Biotechnology Holdings PLC
- Market cap
- GBX 4.84M
- P/E
- -
- P/B
- 70.09x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CIZ.LSE undervalued?
Graham numberThe Graham number of Cizzle Biotechnology Holdings PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cizzle Biotechnology Holdings PLC fundamental analysis
No fundamental analysis for Cizzle Biotechnology Holdings PLC yet.
Cizzle Biotechnology Holdings PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Full company profileCizzle Biotechnology Holdings PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cizzle Biotechnology Holdings PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.32M | 4.55M | 74.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 1.76M | 1.45M | 45.0K | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | -4.00K |
| Operating Income | -1.38M | -2.03M | -1.73M | -21.7K | -229K | 2.26M | -963K | -976K | -878K | -753K | -1.42M |
| EBITDA | -743K | -1.15M | -1.20M | -21.7K | -306K | -851K | -963K | -976K | 2.00 | -753K | -1.41M |
| Net Income | -159.38 | -118.20 | -2.06M | -21.7K | -306K | -3.92M | -912K | -1.72K | -2.17K | -691K | -1.32M |
| EPS | 0.00 | 0.00 | -0.97 | 0.00 | -0.01 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 4.49M | 3.09M | 96.0K | 16.5K | 90.0K | 1.16M | 2.79M | 1.69M | 492K | 245K | 191K |
| Total Liabilities | 2.30M | 2.34M | 331K | 9.85K | 58.0K | 218K | 145K | 186K | 410K | 585K | 528K |
| Shareholders' Equity | 2.19M | 741K | -235K | 6.63K | 32.0K | 937K | 2.64M | 1.51M | 82.0K | -340K | -337K |
| Cash & Short-term Investments | 225K | 44.0K | 4.00K | 12.8K | 84.0K | 875K | 478K | 1.56M | 387K | 116K | 81.0K |
| Total Debt | 831K | 833K | - | - | 10.0K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 186K | -190K | -513K | -7.07K | -294K | -1.01M | -872K | -639K | -358K | -496K | -1.47M |
| Capital Expenditure | 907K | 467K | 176K | 0.00 | 0.00 | 200K | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Free Cash Flow | -721K | -657K | -689K | -7.07K | -294K | -1.21M | -872K | -639K | -358K | -498K | -1.47M |
| Ratios | |||||||||||
| ROE | 0.0% | 0.0% | - | -327.3% | -956.3% | -418.5% | -34.5% | -0.1% | -2.6% | - | - |
| ROA | 0.0% | 0.0% | -2,142.7% | -131.7% | -340.0% | -339.5% | -32.7% | -0.1% | -0.4% | -282.0% | -689.0% |
| Net Profit Margin | 0.0% | 0.0% | -2,779.7% | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.38x | 1.12x | - | - | 0.31x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cizzle Biotechnology Holdings PLC dividends
Cizzle Biotechnology Holdings PLC has not paid dividends in the last 9 fiscal years.
Who owns Cizzle Biotechnology Holdings PLC
- Insiders 34.88%
- Institutions 0.00%
- Public & others 65.12%
- Shares outstanding 425M
- Free float 313M
Cizzle Biotechnology Holdings PLC company profile
- Company name
- Cizzle Biotechnology Holdings PLC
- Ticker
- CIZ.LSE
- ISIN
- GB00BNG2VN02
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- The Shard, London, United Kingdom, SE1 9SG
- Phone
- 44 203 9346630
- Website
- cizzlebiotechnology.com
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Cizzle Biotechnology Holdings PLC management
3- Dr. Allan John SymsExecutive Chairman · born 1956
- Prof. Dawn CoverleyFounder, Chief Scientific Officer & Executive Director · born 1965
- Mr. Nigel R. LeeFinance Director & Executive Director · born 1961